Thus, it is suggested that IL-22 may be a useful therapeutic tool in T2DM patients with tuberculosis infection, especially since serum levels of this cytokine are significantly lower in such patients relative to T2DM patients uninfected with the intracellular pathogen [47]. The gene discussed is IL22; the disease is type 2 diabetes mellitus.